Management of hepatitis B virus (HBV) reactivation in patients with resolved HBV infection based on a highly sensitive HB core‐related antigen assay
Shinya Hagiwara(Nagoya City University), Yasuhito Tanaka(Kumamoto University), Masaki Ri(Nagoya University Hospital), Katsumi Aoyagi(Fujirebio (Japan)), Atsushi Kaneko(Japanese Red Cross Nagoya Daiichi Hospital), Asahi Ito(Nagoya City University), Shinsuke Iida(Nagoya City University Hospital), Takako Inoue(Kaneka (United States)), Takanori Suzuki(Nagoya City University), Shintaro Yagi(Advanced Life Science Institute), Kentaro Matsuura(Nagoya City University), Hirokazu Komatsu(Nagoya City University), Tomoko Narita(Nagoya City University), Shintaro Ogawa(Nagoya City University), Shigeru Kusumoto
Cited by 15
Related Papers
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
|The Lancet Haematology|2019|247
Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization
|Proceedings of the National Academy of Sciences|2019|241
Gut Dysbiosis Associated With Hepatitis C Virus Infection
|Clinical Infectious Diseases|2018|187